ADMA Biologics Inc (ADMA)
6.945
+0.08
(+1.24%)
USD |
NASDAQ |
May 09, 16:00
7.75
+0.80
(+11.59%)
After-Hours: 20:00
ADMA Biologics SG&A Expense (Quarterly): 15.54M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 15.54M |
September 30, 2023 | 14.73M |
June 30, 2023 | 14.25M |
March 31, 2023 | 14.51M |
December 31, 2022 | 13.89M |
September 30, 2022 | 12.89M |
June 30, 2022 | 11.97M |
March 31, 2022 | 13.70M |
December 31, 2021 | 11.70M |
September 30, 2021 | 10.73M |
June 30, 2021 | 10.44M |
March 31, 2021 | 10.03M |
December 31, 2020 | 9.300M |
September 30, 2020 | 9.116M |
June 30, 2020 | 8.703M |
March 31, 2020 | 7.932M |
December 31, 2019 | 7.032M |
September 30, 2019 | 7.197M |
June 30, 2019 | 6.086M |
March 31, 2019 | 5.596M |
December 31, 2018 | 6.073M |
September 30, 2018 | 5.670M |
June 30, 2018 | 5.438M |
March 31, 2018 | 5.321M |
December 31, 2017 | 5.844M |
Date | Value |
---|---|
September 30, 2017 | 4.196M |
June 30, 2017 | 4.436M |
March 31, 2017 | 4.277M |
December 31, 2016 | 3.284M |
September 30, 2016 | 1.779M |
June 30, 2016 | 1.724M |
March 31, 2016 | 1.708M |
December 31, 2015 | 1.884M |
September 30, 2015 | 2.078M |
June 30, 2015 | 1.437M |
March 31, 2015 | 1.346M |
December 31, 2014 | 1.112M |
September 30, 2014 | 1.035M |
June 30, 2014 | 1.542M |
March 31, 2014 | 1.135M |
December 31, 2013 | 0.9986M |
September 30, 2013 | 0.8453M |
June 30, 2013 | 1.090M |
March 31, 2013 | 1.431M |
December 31, 2012 | 0.6962M |
September 30, 2012 | 1.034M |
June 30, 2012 | 0.7369M |
March 31, 2012 | 0.6746M |
December 31, 2011 | 0.0039M |
September 30, 2011 | 0.0039M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
6.086M
Minimum
Jun 2019
15.54M
Maximum
Dec 2023
11.04M
Average
10.73M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Vanda Pharmaceuticals Inc | 23.61M |
ANI Pharmaceuticals Inc | 44.46M |
Ligand Pharmaceuticals Inc | 10.95M |
Johnson & Johnson | 5.057B |
Puma Biotechnology Inc | 21.64M |